Crossmark Global Holdings Inc. bought a new position in Bioverativ Inc (NASDAQ:BIVV) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 17,437 shares of the biotechnology company’s stock, valued at approximately $995,000.
A number of other large investors also recently made changes to their positions in BIVV. Quotient Investors LLC purchased a new position in Bioverativ in the third quarter worth $420,000. Mutual of America Capital Management LLC purchased a new position in Bioverativ in the third quarter worth $5,062,000. Meeder Asset Management Inc. purchased a new position in Bioverativ in the third quarter worth $877,000. Rockefeller Financial Services Inc. purchased a new position in Bioverativ in the third quarter worth $1,480,000. Finally, State Treasurer State of Michigan purchased a new position in Bioverativ in the third quarter worth $2,323,000. Institutional investors own 93.07% of the company’s stock.
COPYRIGHT VIOLATION WARNING: “Crossmark Global Holdings Inc. Buys New Stake in Bioverativ Inc (BIVV)” was originally posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another site, it was illegally stolen and republished in violation of United States & international copyright and trademark legislation. The original version of this report can be viewed at https://www.dispatchtribunal.com/2017/11/12/crossmark-global-holdings-inc-buys-new-stake-in-bioverativ-inc-bivv.html.
Bioverativ Inc (NASDAQ:BIVV) opened at $53.66 on Friday. Bioverativ Inc has a one year low of $40.00 and a one year high of $64.41.
Bioverativ (NASDAQ:BIVV) last issued its quarterly earnings data on Thursday, October 26th. The biotechnology company reported $0.80 EPS for the quarter, beating the consensus estimate of $0.55 by $0.25. The firm had revenue of $291.60 million during the quarter, compared to the consensus estimate of $285.45 million. Bioverativ had a net margin of 40.44% and a return on equity of 69.03%. The firm’s revenue for the quarter was up 27.2% on a year-over-year basis. analysts expect that Bioverativ Inc will post 2.45 earnings per share for the current year.
Several research analysts recently issued reports on BIVV shares. Zacks Investment Research upgraded shares of Bioverativ from a “hold” rating to a “strong-buy” rating and set a $73.00 target price for the company in a research report on Tuesday, July 25th. Cowen and Company reissued a “buy” rating and issued a $80.00 price target on shares of Bioverativ in a research note on Friday, August 4th. Royal Bank Of Canada assumed coverage on shares of Bioverativ in a research note on Thursday, September 14th. They issued a “sector perform” rating and a $59.00 price target for the company. Evercore ISI assumed coverage on shares of Bioverativ in a research note on Wednesday, August 16th. They issued an “in-line” rating and a $58.00 price target for the company. Finally, Argus raised shares of Bioverativ from a “hold” rating to a “buy” rating and set a $64.00 price target for the company in a research note on Wednesday, September 20th. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Hold” and an average target price of $61.73.
Bioverativ Inc (Bioverativ) is a biotechnology company. The Company is focused on the discovery, research, development and commercialization of therapies for the treatment of hemophilia and other blood disorders. It markets approximately two products, including ELOCTATE [Antihemophilic Factor (Recombinant), Fc Fusion Protein], and ALPROLIX [Coagulation Factor IX (Recombinant), Fc Fusion Protein], extended half-life clotting-factor therapies for the treatment of hemophilia A and hemophilia B, respectively.
Want to see what other hedge funds are holding BIVV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bioverativ Inc (NASDAQ:BIVV).
Receive News & Ratings for Bioverativ Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bioverativ Inc and related companies with MarketBeat.com's FREE daily email newsletter.